中华内分泌代谢杂志
中華內分泌代謝雜誌
중화내분비대사잡지
CHINESE JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2011年
11期
887-891
,共5页
肖园%董治亚%陆文丽%王秀民%孙文鑫%王德芬%倪继红%陈凤生%王俊祺%王伟
肖園%董治亞%陸文麗%王秀民%孫文鑫%王德芬%倪繼紅%陳鳳生%王俊祺%王偉
초완%동치아%륙문려%왕수민%손문흠%왕덕분%예계홍%진봉생%왕준기%왕위
生长激素治疗%生长激素缺乏症%特发性矮小症%胰岛素样生长因子Ⅰ%C型利钠肽
生長激素治療%生長激素缺乏癥%特髮性矮小癥%胰島素樣生長因子Ⅰ%C型利鈉肽
생장격소치료%생장격소결핍증%특발성왜소증%이도소양생장인자Ⅰ%C형리납태
Growth hormone treatment%Growth hormone deficiency%Idiopathic short stature%Insulinlike growth factor- Ⅰ%C-type natriuretic peptide
目的 探讨单纯性生长激素缺乏症(isolated growth hormone deficiency,IGHD)以及特发性矮小症(idiopathic short stature,ISS)患儿经重组人生长激素(recombinant human growth hormone,rhGH)治疗后,血清C型利钠肽氨基末端(NTproCNP)浓度的变化及其与生长速率(growth velocity,GV)的关系.方法 共有48例青春期前的患儿纳入研究(IGHD 25例,ISS 23例),并给予rhGH治疗1年.治疗前及治疗后6个月分别测血清胰岛素样生长因子-Ⅰ (IGF-Ⅰ)和NTproCNP的浓度.治疗1年后,计算所有患儿的GV、身高Z积分(HTSDS)以及身高Z积分的变化值(△HTSDS).结果 IGHD组中,治疗前后IGF-I Z积分的变化值(△IGF-ISDS)、NTproCNP浓度的变化值(△NTproCNP)与治疗1年中GV呈正相关(r=0.407,P=0.044；r=0.490,P=0.013)；治疗前生长激素(CH)峰值也与治疗前IGF-ISDS、NTproCNP浓度(r=0.558,P=0.004;r=0.630,P=0.001)以及治疗后△IGF-ISDS与△NTproCNP呈正相关(r=0.466,P=0.019).而在ISS患儿中,治疗1年中GV只与治疗后△NTproCNP相关(r=0.845,P＜0.01).结论 在IGHD和ISS患儿应用rhGH的促生长治疗中,NTproCNP水平随着生长速率的增加而增加.因此除了IGF-I,NTproCNP作为一种新的生化标记物,也可用于评估和预测这两类患儿在rhGH治疗后的GV变化.
目的 探討單純性生長激素缺乏癥(isolated growth hormone deficiency,IGHD)以及特髮性矮小癥(idiopathic short stature,ISS)患兒經重組人生長激素(recombinant human growth hormone,rhGH)治療後,血清C型利鈉肽氨基末耑(NTproCNP)濃度的變化及其與生長速率(growth velocity,GV)的關繫.方法 共有48例青春期前的患兒納入研究(IGHD 25例,ISS 23例),併給予rhGH治療1年.治療前及治療後6箇月分彆測血清胰島素樣生長因子-Ⅰ (IGF-Ⅰ)和NTproCNP的濃度.治療1年後,計算所有患兒的GV、身高Z積分(HTSDS)以及身高Z積分的變化值(△HTSDS).結果 IGHD組中,治療前後IGF-I Z積分的變化值(△IGF-ISDS)、NTproCNP濃度的變化值(△NTproCNP)與治療1年中GV呈正相關(r=0.407,P=0.044；r=0.490,P=0.013)；治療前生長激素(CH)峰值也與治療前IGF-ISDS、NTproCNP濃度(r=0.558,P=0.004;r=0.630,P=0.001)以及治療後△IGF-ISDS與△NTproCNP呈正相關(r=0.466,P=0.019).而在ISS患兒中,治療1年中GV隻與治療後△NTproCNP相關(r=0.845,P＜0.01).結論 在IGHD和ISS患兒應用rhGH的促生長治療中,NTproCNP水平隨著生長速率的增加而增加.因此除瞭IGF-I,NTproCNP作為一種新的生化標記物,也可用于評估和預測這兩類患兒在rhGH治療後的GV變化.
목적 탐토단순성생장격소결핍증(isolated growth hormone deficiency,IGHD)이급특발성왜소증(idiopathic short stature,ISS)환인경중조인생장격소(recombinant human growth hormone,rhGH)치료후,혈청C형리납태안기말단(NTproCNP)농도적변화급기여생장속솔(growth velocity,GV)적관계.방법 공유48례청춘기전적환인납입연구(IGHD 25례,ISS 23례),병급여rhGH치료1년.치료전급치료후6개월분별측혈청이도소양생장인자-Ⅰ (IGF-Ⅰ)화NTproCNP적농도.치료1년후,계산소유환인적GV、신고Z적분(HTSDS)이급신고Z적분적변화치(△HTSDS).결과 IGHD조중,치료전후IGF-I Z적분적변화치(△IGF-ISDS)、NTproCNP농도적변화치(△NTproCNP)여치료1년중GV정정상관(r=0.407,P=0.044；r=0.490,P=0.013)；치료전생장격소(CH)봉치야여치료전IGF-ISDS、NTproCNP농도(r=0.558,P=0.004;r=0.630,P=0.001)이급치료후△IGF-ISDS여△NTproCNP정정상관(r=0.466,P=0.019).이재ISS환인중,치료1년중GV지여치료후△NTproCNP상관(r=0.845,P＜0.01).결론 재IGHD화ISS환인응용rhGH적촉생장치료중,NTproCNP수평수착생장속솔적증가이증가.인차제료IGF-I,NTproCNP작위일충신적생화표기물,야가용우평고화예측저량류환인재rhGH치료후적GV변화.
Objective To explore the value of amino-terminal propeptide of C-type natriuretic peptide (NTproCNP) in evaluating the efficacy of therapy with recombinant human growth hormone ( rhGH ) in patients with idiopathic short stature (ISS) and isolated growth hormone deficiency ( IGHD ).Methods Forty-eight prepubertal children( IGHD n=25,ISS n=23 ) treated for at least 1 year with rhGH were included.Serum insulin-like growth factor- Ⅰ ( IGF- Ⅰ ) and NTproCNP levels were measured before starting treatment and 6 months later.Twelve months after starting treatment,all patients were assessed and annual growth velocity ( GV ),height standard deviation score ( HTSDS),and gained HTSDS (△HTSDS) were recorded.Results In GHD group,positive relationships between GV and change of IGF- ISDS( △IGF- ISDS ),GV and change of NTproCNP concentrations(△NTproCNP) were found( r=0.407,P=0.044 ;r=0.490,P=0.013 ).GH peak value was also positively associated with IGF- ISDS and NTproCNP before therapy ( r =0.558,P =0.004; r =0.630,P =0.001 ).△IGF- ISDS and △NTproCNP were positively associated after therapy ( r =0.466,P =0.019 ).In ISS group,GV was associated with △NTproCNP ( r=0.845,P＜ 0.01 ).Conclusions NTproCNP is a novel biomarker of growth as its level increases during growth-promoting treatment.Furthermore,IGF- Ⅰ is also valuable in evaluating the efficacy of rhGH therapy in short stature patients.
